<DOC>
	<DOC>NCT00162149</DOC>
	<brief_summary>Open-Label, multiple-dose, drug interaction study to assess the effect of nevirapine on the pharmacokinetics of atazanavir in HIV-infected individuals.</brief_summary>
	<brief_title>ATV/Ritonavir Nevirapine Interaction (USPAC)</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<criteria>signed informed consent form For Cohort 1, HIVinfected subjects receiving nevirapine 200 mg twicedaily and 2 to 3 NRTIs for at least 6 weeks For Cohort 2, HIVinfected subjects receiving atazanavir 300 mg and ritonavir 100 mg oncedaily and 2 to 3 NRTIs for at least 6 weeks Have had 2 measurements of plasma HIV RNA of &lt;400 copies/mL. The first test being 6 to 16 weeks prior and the second being within 3 weeks prior to Day 1 Have CD4 cell count &gt;=200 cells/mm3 Body Mass Index of 18 to 35 kg/m2. Men and women, ages 18 to 55. Women who are pregnant or breastfeeding Presence of a newly diagnosed HIVrelated opportunistic infection or CD4 cell count &lt;200 cell/mm3 within the previous 6 months. Any significant acute or chronic medical illness, unless stable or controlled by a nonprohibited medication. History of virologic failure on an antiretroviral regimen.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>